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Background: Atrial Fibrillation (AF) is a common arrhythmia in the US affecting nearly 2.3 million patients. Dronedarone (DR), a non-iodinated 
benzofuran derivative, was recently approved for the prevention of cardiovascular hospitalization related to AF based on the results of the ATHENA 
trial. We pooled data from other trials to evaluate the efficacy of DR in preventing AF recurrence.
Methods: We performed a meta-analysis of 4 trials (DAFNE, ADONIS, EURIDIS, ATHENA) that evaluated the antiarrhythmic efficacy of DR compared 
with placebo. The pooled estimates for the relative risk of recurrence of AF with DR were derived via a fixed-effects Mantel Haenszel model. 
Heterogeneity was assessed via Colchran’s Q and I2 tests.
Results: A total of 4812 patients were analyzed, 2614 in the DR arm versus 2198 in the placebo arm. Pooled data demonstrated that 43% of DR-
treated patients had an AF recurrence compared with 54% of placebo-treated patients, representing an absolute risk reduction of 11% (NNT=9). The 
relative risk was 0.82 (95% CI 0.77 to 0.87); p<0.0001.
Conclusion: Our results show a modest efficacy of DR in maintaining sinus rhythm in patients with AF compared to placebo. These results are 
comparable with those achieved by earlier agents (quinidine) and significantly less than those reported with amiodarone. Long-term studies are 
required to conclusively establish the antiarrhythmic efficacy and safety of dronedarone. Until then its use should be reserved as a second- or third-
line agent for treatment of AF. 
